Dashboard
Manage Tickers

ALVOAlvotech

Nasdaq alvotech.com


$ 12.39 $ -0.25 (-1.98 %)    

Wednesday, 21-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 12.4
$ 12.38 x 159
-- x --
-- - --
$ 8.29 - $ 18.00
255,796
na
3.31B
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

alvotech-files-for-offering-of-up-to-18m-shares-by-the-selling-shareholder
Alvotech Files For Offering Of Up To 1.8M ...
08/21/2024 20:28:21

-SEC Filing

vipshop-hesai-group-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Vipshop, Hesai Group And Other Big Stocks ...
08/20/2024 12:16:33

alvotech-h1-2024-eps-061-vs-039-yoy-revenue-236m-vs-203m-yoy
Alvotech H1 2024 EPS $(0.61) Vs $(0.39) Yo...
08/15/2024 20:24:33

ema-accepts-alvotech-and-advanz-pharmas-application-for-eylea-biosimilar
EMA Accepts Alvotech and Advanz Pharma's A...
08/15/2024 08:32:24

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

barclays-maintains-overweight-on-alvotech-lowers-price-target-to-18
Barclays Maintains Overweight on Alvotech,...
07/25/2024 12:23:02

Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and lowers the price target from $22 to $18.

stada-and-alvotech-launch-uzpruvo-first-stelara-biosimilar-in-europe
STADA and Alvotech Launch Uzpruvo, First S...
07/22/2024 10:36:42

 STADA and Alvotech have launched Uzpruvo®, the first approved biosimilar to Stelara® in Europe, across a majority of European ...

alvotech-announces-topline-results-from-confirmatory-patient-study-for-avt03-a-proposed-biosimilar-for-prolia-and-xgeva
Alvotech Announces Topline Results From Co...
07/02/2024 13:13:41

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two addi...

alvotech-announces-q2-preliminary-revenue-of-196m-201m-vs-160m-est-preliminary-adj-ebitda-of-98m-103m
Alvotech Announces Q2 Preliminary Revenue ...
07/01/2024 09:14:15

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

alvotech-received-conversion-notices-for-majority-of-convertible-bonds-into-ordinary-shares-at-the-fixed-conversion-price-of-1000-per-share-prior-to-maturity-date-of-july-1-2024
Alvotech Received Conversion Notices for M...
06/26/2024 08:56:24

alvotech-inks-commercialization-agreement-with-advanz-pharma-for-proposed-biosimilar-to-eylea-ldhd-in-europe
Alvotech Inks Commercialization Agreement ...
06/18/2024 08:09:08

Advanz Pharma secures rights to commercialize Alvotech's biosimilar candidate for Eylea® in Europe Advanz Pharma will le...

alvotech-sa-may-offer-and-sell-ordinary-shares-of-up-to-75m-from-time-to-time-entered-into-open-market-sale-agreement-with-jefferies-relating-to-sale-of-ordinary-shares
Alvotech SA May Offer And Sell Ordinary Sh...
06/14/2024 20:38:28

- SEC Filing

alvotech-and-stada-extend-partnership-through-avt03-biosimilar-candidate-addition
Alvotech And STADA Extend Partnership Thro...
06/11/2024 08:17:36

Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facili...

alvotech-secures-965m-refinancing-deal-to-boost-financial-flexibility-and-support-product-launches
Alvotech Secures $965M Refinancing Deal to...
06/07/2024 08:03:12

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

barclays-maintains-overweight-on-alvotech-raises-price-target-to-22
Barclays Maintains Overweight on Alvotech,...
05/24/2024 15:03:19

Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and raises the price target from $20 to $22.

alvotech-now-sees-fy24-revenue-of-400m-500m-est-318575m
Alvotech Now Sees FY24 Revenue Of $400M-$5...
05/21/2024 21:33:10

Alvotech tightened guidance for EBIDTA to $100 - $150 million for the full year.

alvotech-q1-2024-sales-36894m-miss-45000m-estimate
Alvotech Q1 2024 Sales $36.894M Miss $45.0...
05/21/2024 21:22:29

alvotech-q1-2024-gaap-eps-089-up-from-124-yoy
Alvotech Q1 2024 GAAP EPS $(0.89) Up From ...
05/21/2024 21:20:08

Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.89) per share. This is a 28.23 percent increase over losses of $(1.24) ...

stocks-hold-steady-on-mixed-fed-remarks-first-solar-rallies-bitcoin-falls-below-70000-whats-driving-markets-tuesday
Stocks Hold Steady On Mixed Fed Remarks, F...
05/21/2024 16:42:40

It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.

Core News & Articles
Alvotech And Dr. Reddy's Enter Collaborato...
05/21/2024 12:05:27

Core News & Articles
Reported Earlier, Teva And Alvotech Announ...
05/21/2024 06:57:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION